Tetrakosaktid Kullanımına Bağlı Gelişen Hipokalemik Kuadriparezi

Öz

Hypokalemic periodic paralysis (HPP) is a rare disease characterized by reversible attacks of muscle weakness accompanied by episodic hypokalemia. The most common causes of HPP are familial periodic paralysis (FPP), thyrotoxic periodic paralysis (TPP) and sporadic periodic paralysis (SPP). A male patient admitted to our emergency services had weakness in his upper and lower extremities due to using tetracosactide. Patient was diagnosed as hypokalemic paralysis based upon laboratory examination and history. The epidemiology, pathophysiology, clinical presentation and therapy of this relatively rare disease were reviewed.

Anahtar Kelimeler

• Hypokalemia, quadriparesis, tetracosactide

Hypokalemic Quadriparesis due to Use of Tetracosactide

Öz

Hypokalemic periodic paralysis (HPP) is a rare disease characterized by reversible attacks of muscle weakness accompanied by episodic hypokalemia. The most common causes of HPP are familial periodic paralysis (FPP), thyrotoxic periodic paralysis (TPP) and sporadic periodic paralysis (SPP). A male patient admitted to our emergency services had weakness in his upper and lower extremities due to using tetracosactide. Patient was diagnosed as hypokalemic paralysis based upon laboratory examination and history. The epidemiology, pathophysiology, clinical presentation and therapy of this relatively rare disease were reviewed

Anahtar Kelimeler

• Hypokalemia, quadriparesis, tetracosactide

Kaynakça

1. Stedwell RE, Allen KM, Binder LS. Hypokalemic paralyses: a re- view of the etiologies, pathophysiology, presentation and therapy. Am J Emerg Med. 1992; 10: 143-6. [CrossRef]
2. Ahlawat SK, Sachdev A. Hypokalemic paralysis. Postgrad Med J. 1999; 75: 193-7.
3. Lin SH, Lin YF, Halperin ML. Hypokalemia and paralysis. QJM. 2001; 94: 133-9. [CrossRef]
4. Akar S, Comlekci A, Birlik M, Onen F, Sari I, Gurler O, et al. Thyro- toxic periodic paralysis in a Turkish male; the recurrence of the attack after radioiodine treatment. Endocr J. 2005; 52: 149-51. [CrossRef]
5. Koc F, Bozdemir H, Över F, Sarıca Y. Tirotoksik hipokalemik peri- yodik paralizi; 7 olgunun analizi ve literatürün gözden geçirilmesi. Gülhane Tıp Dergisi. 2004; 46: 59-65.
6. Antes LM, Kujubu DA, Fernandez PC. Hypokalemia and the pathol- ogy of ion transport molecules. Semin Nephrol. 1998; 18: 31-45.
7. Gutmann L. Periodic paralyses. Neurol Clin. 2000; 18: 195-202. [CrossRef]
8. Gennari FJ. Hypokalemia. N Engl J Med. 1998; 339: 451-8. [CrossRef]

9. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004; 43: 155-61. [CrossRef]
10. Adams RD, Victor M. Myasthenia Gravis and episodic forms of muscular weakness. In: Principles of neurology. McGraw-Hill In- formation Services Company; 1989. p. 1150-67.
11. Rowland LP. Hypokalemic periodic paralysis. In: Rowland LP, editor. Merritt’s neurology. 10th ed. Philadelphia: Lippincott Wil- liams and Wilkins; 2000. p. 749-52.
12. Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic fea- tures of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med. 1999; 159: 601-6. [CrossRef]
13. Shulkin D, Olson BR, Levey GS. Thyrotoxic periodic paralysis in a Latin-American taking acetazolamide. Am J Med Sci. 1989; 297: 337-8. [CrossRef]
14. Shayne P, Hart A. Thyrotoxic periodic paralysis terminated with intravenous propranolol. Ann Emerg Med. 1994; 24: 736-40. [CrossRef]